drugset / Trial / NCT05288829
A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants
RandomizedParallel-groupDouble-blindBasic science
Summary
This study evaluated the safety and tolerability of a single dose of ALXN1210 subcutaneous (SC) compared to ALXN1210 intravenous (IV) in healthy participants and to determine the absolute bioavailability of ALXN1210 SC.
Timeline
- Start
- 2016-08-19
- Primary completion
- 2017-07-18
- Completion
- 2017-07-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ravulizumab | Monoclonal antibody | 400 mg | Subcutaneous |
Indications
No indication recorded.